Vestal Point Capital, LP Xenon Pharmaceuticals Inc. Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 525,000 shares of XENE stock, worth $21.9 Million. This represents 1.53% of its overall portfolio holdings.
Number of Shares
525,000
Previous 400,000
31.25%
Holding current value
$21.9 Million
Previous $17.2 Billion
18.87%
% of portfolio
1.53%
Previous 1.42%
Shares
3 transactions
Others Institutions Holding XENE
# of Institutions
222Shares Held
69.8MCall Options Held
59.7KPut Options Held
60.7K-
Avoro Capital Advisors LLC New York, NY5.67MShares$236 Million3.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.42MShares$184 Million1.86% of portfolio
-
Wellington Management Group LLP Boston, MA3.83MShares$160 Million0.03% of portfolio
-
Commodore Capital LP New York, NY2.75MShares$115 Million9.63% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$112 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.6B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...